ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

被引：0
|
作者：
Essers, B. A. [1 ]
Tjan, Heijnen, V [1 ]
Severens, J. L. [1 ]
Novak, A. [2 ]
Oron, U. [3 ]
Pompen, M. [4 ]
Joore, M. A. [1 ]
机构：
[1] Univ Hosp Maastricht, Maastricht, Netherlands
[2] Anovak Serv, Apeldoorn, Netherlands
[3] Roche, Woerden, Netherlands
[4] Roche Netherland BV, Woerden, Netherlands
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66577-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A472 / A472
页数：1
相关论文
共 50 条
  • [1] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
  • [2] ECONOMIC EVALUATION OF ADJUVANT TRASTUZUMAB IN THE TREATMENT OF EARLY, HER2/NEU-OVEREXPRESSING BREAST CANCER IN SINGAPORE
    Lopes, G. De Lima
    EJC SUPPLEMENTS, 2011, 9 (01): : 8 - 8
  • [3] An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
    Antonio Buendia, Jefferson
    Vallejos, Carlos
    Pichon-Riviere, Andres
    BIOMEDICA, 2013, 33 (03): : 411 - 417
  • [4] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [5] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    Lluch-Gomez, J.
    Nunez-Alvarez, V.
    de la Torre-Hita, C.
    Bernal-Gomez, M.
    Campini-Bermejo, A.
    Perdomo-Zaldivar, E.
    Rodriguez-Perez, L.
    Calvete-Candenas, J.
    Martinez-Bautista, M. J.
    Benitez-Rodriguez, E.
    Baena-Canada, J. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
  • [7] TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS
    Joore, M. A.
    Heijnen, Tjan, V
    Severens, J. L.
    Novak, A.
    Oron, U.
    Pompen, M.
    Essers, B. A.
    VALUE IN HEALTH, 2008, 11 (06) : A347 - A347
  • [8] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [9] Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands
    Essers, Brigitte A. B.
    Seferina, Shanley C.
    Tjan-Heijnen, Vivianne C. G.
    Severens, Johan L.
    Novak, Annoesjka
    Pompen, Marjolein
    Oron, Ulrich H.
    Joore, Manuela A.
    VALUE IN HEALTH, 2010, 13 (04) : 375 - 380
  • [10] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
    Baselga, Jose
    Perez, Edith A.
    Pienkowski, Tadeusz
    Bell, Richard
    ONCOLOGIST, 2006, 11 : 4 - 12
12345